I don't know what Bell Potter said in their update, but the title appears to be "Another Strong Clinical Result: KEYNOTE-200 Data Better Than Expected"
according to the vla website.
https://www.viralytics.com/investor-centre/analysts-reports/analyst-coverage-2017/